The primary outcome is level of stress as measured with HRV on day 5 overnight from the whole sleeping time as defined from the HRV and movement data as recorded by the HRV device.
The secondary outcomes are sleep quality, nausea and vomiting, pain intensity, analgesics consumption, sedatives consumption, emetics consumption, mood, grade of mobilization, length of stay in hospital, complications associated with the RE-therapy. Nursing students will be asked regularly about job satisfaction (UWES), empathy and motivation to carry out the RE.
PERIODS
|
|
Baseline
|
Intervention
|
|
Follow-Up
|
VISITS
|
Screening / Consent
|
Surgery / ICU
|
Visit 1 (Baseline)
|
|
Visit 2
|
|
|
Final Visit
EOT
|
|
Time
|
Day − 1 (day before surgery)
|
Day X-Y
|
Day 1 (arrival on regular ward)
|
Day 2
|
Day 3
|
Day 4
|
Day 5
|
Day 6
|
|
Informed consent
|
X
|
|
|
|
|
|
|
|
|
Inclusion / Exclusion criteria, demographic data
|
X
|
|
(X)*
|
|
|
|
|
|
|
Medical history, surgery type / length / complications
|
|
|
X
|
|
|
|
|
(X)*
|
|
Sleeping habits, movement habits,
stress factors
|
X
|
|
|
|
|
|
|
|
|
Randomization
|
|
|
X
|
|
|
|
|
|
|
Vital signs (RR, Temp., bowel activity)
|
|
|
X
|
X, X
|
X, X
|
X, X
|
X, X
|
X
|
|
Mobility (EBoMo)
|
|
|
X
|
|
|
|
|
X
|
|
24-ECG (HRV)
|
|
|
X
|
|
|
|
X
|
|
|
Intervention morning
|
|
|
|
X
|
X
|
X
|
X
|
|
|
Intervention evening
|
|
|
|
X
|
X
|
X
|
X
|
|
|
Pain (VAS)
|
|
|
X
|
|
X
|
|
|
X
|
|
Nausea (VAS)
|
|
|
X
|
|
X
|
|
|
X
|
|
Vomiting episodes
|
|
|
X
|
|
X
|
|
|
X
|
|
Sleep (RCSQ)
|
|
|
|
X
|
X
|
|
|
X
|
X
|
Mood (MDBF)
|
|
|
X
|
|
X
|
|
|
X
|
X
|
Pregnancy test
|
|
|
X
|
|
|
|
|
|
|
Complications / other details of RE
|
|
|
X
|
X
|
X
|
X
|
X
|
X
|
|
Medication
|
|
|
X
|
|
X
|
|
|
X
|
X
|
Length of stay
|
|
|
|
|
|
|
|
X
|
|
Abbreviations: ICU: intensive care unit; EOT: end of trial; RR: blood pressure; EBoMo: Evaluationsbogen Mobilität – evaluation sheet mobility; ECG: electrocardiogram; HRV: heart rate variability; VAS: visual analogue scale; RCSQ: Richards Campbell sleep questionnaire; MDBF: Mehrdimensionaler Befindlichkeitsfragebogen – multidimensional mood questionnaire; RE: rhythmical embrocations. *Inclusion and exclusion criteria will be checked again on day 1. |
Sample size {14}
The sample size calculation is based on the data of a previous trial investigating perioperative stress with heart rate variability as outcome measure. In that trial, significant changes in the SDNN had been recorded at different perioperative time points [6]. The preoperative SDNN was 116 milliseconds (ms); on day one after surgery it was 65 ms, and on postoperative day seven it was 87 ms (values are approximate values as the concrete values are not given in the article text, but only displayed as a bar chart; because the authors did not answer to our request, we converted the bar chart into numbers using WebPlotDigitizer [28]). Based on these figures, we presume the median SDNN in the conversation group to be 80 ms on postoperative day 5. In the intervention groups, we presume a faster recovery of the SDNN; i.e., 110 ms on day 5 (therefore we set δ=30). In the previous trial, the standard deviation was around 30 (σ=30) for all measurements. Based on a t-distribution, a two-tailed α=0.05 and a power (β) of 0.8, we calculated a sample size of 17 patients per group, and thus 51 in total. To adjust for attrition, we will enroll 60 patients.
Recruitment {15}
In the surgical department 120 patients are operated on each year who match the inclusion criteria of our study. We therefore consider a recruitment rate of 60 in 12 months to be feasible. We expect a small dropout rate because data collection encompasses five days only and eligible patients are already hospitalized.
Assignment of interventions: allocation
Sequence generation {16a}
For allocation to the various trial arms, a computer-generated list of random numbers will be used. The list will be retrieved by an independent researcher only and randomization will be performed from this list for each individual patient after inclusion in the study.
Concealment mechanism {16b}
The allocation sequence is generated by an independent researcher using the website Randomization.com [29]. No stratification or block randomization is used.
Implementation {16c}
The participants are enrolled by a doctor at the pre-surgical visit. The inclusion and exclusion criteria are checked again after surgery at arrival on the normal ward. After inclusion of a new patient, the investigator and the trial assistant are informed. The investigator or the trial assistant sends the sequential number of the new patient electronically to the independent researcher, upon which the independent researcher sends back the code of intervention from the allocation list.
Assignment of interventions: Blinding
Who will be blinded {17a}
All study staff who are directly involved in the intervention (RE experts, nursing students) cannot be blinded. Study stuff providing RE are instructed not to inform the patients if they are treated by experts or students. The patients are informed in the patient information, that they will not be told if they are treated bey experts or students in the intervention arms with RE. Data collection and data analysis will be blinded.
Procedure for unblinding if needed {17b}
Not applicable
Data collection and management
Plans for assessment and collection of outcomes {18a}
The primary outcome ‘level of stress’ will be assessed from the heart rate variability (HRV), which will be recorded on days 1 and 5 overnight using a one-channel electrocardiogram (ECG, Bittium Faros 180 [30]). Data will be processed according to the 1996 guideline of the Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology [5].
The secondary outcomes will be assessed as follows: Sleep quality with the Richards-Campbell sleep questionnaire (RCSQ) in its German validated translation [31] on days 2, 3 and 6. The severity of nausea within the last 24 hours will be assessed using a 100 mm visual analogue scale (VAS, from: no nausea to: worst imaginable nausea) [32, 33] on days 1, 3 and 6. Number of vomiting episodes within the last 24 hours will be documented [32] on days 1, 3 and 6. Pain within the last 24 hours will be assessed on days 1, 3 and 6 using a 100 mm VAS (from: no pain to: strongest imaginable pain). Consumption of analgesics, sedatives, emetics and other relevant medication will be retrieved from the patient’s chart. Mood will be assessed on days 1, 3 and 6 using the Mehrdimensionaler Befindlichkeitsfragebogen (MDBF, Multidimensional well-being questionnaire, a validated questionnaire measuring well-being in the dimensions of pleasant – unpleasant, awake – sleepy, and calm – restless [34]). For the assessment of activity level, the Evaluationsbogen Mobilität (EBoMo, mobility evaluation sheet, a simple scoring tool for activity level e.g. in nursing homes [35]) will be scored at baseline and on day 6.
Length of stay in the hospital will be recorded as indicated in the patient’s chart. Regarding complications associated with the intervention, patients will be asked to report these before the evening treatment.
The RCSQ and MDBF will be mailed to the participants 1 month after discharge. They will be telephoned and asked to fill out the questionnaires and send them back to the study center in the pre-paid envelope. In addition, they will also be asked to indicate current medication consumption, especially sleep medication and tranquilizing drugs. At the start and end of the trial and every 3 months during the trial, the nursing students will be asked to fill out the following validated questionnaires: Utrecht Work Engagement Scale – Short form (UWES-9) [36], Interpersonal Reactivity Index (IRI) [37]. At the end of their work in the trial they will fill out the questionnaire: Inner Correspondence and feelings of Peaceful Relief (ICPH) [38].
Plans to promote participant retention and complete follow-up {18b}
Regarding the short time for each participant in the trial, we expect we do not have to promote participant retention or collect outcome data for participants who discontinue or deviate from intervention protocols.
Data management {19}
HRV data will be extracted and analyzed using Matlab (The Mathworks) [39].
Data of questionnaires and open questions will be collected on paper in prepared questionnaires and data sheets. This data will be collected and managed using REDCap (Research Electronic Data Capture) tools hosted at the University Medical Center Freiburg [40]. REDCap is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. The data will be entered into REDCap 10.0.28 into fields with prespecified data ranges and plausibility checks.
The datasets from Matlab and REDCap will then be merged by patient id.
Confidentiality {27}
All patient data is collected and processed pseudonymously. The ID list with the patients’ names will only be available to the trial investigator. The trial data is only accessible to the trial investigator and authorized personnel.
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Not applicable
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Data analysis will be performed using R 4.0.3 (or higher) [41]. Data-analysis will be performed with an intention-to-treat approach using the full analysis set. A p-value < 0.05 will be regarded as indicating significance.
For the primary outcome ‘level of stress’, the SDNN will be calculated from HRV during sleep from the recording of day 5; the mean and standard deviation of each intervention group will be calculated. The following testing sequence will then be performed: the mean with standard deviation of the control group (empathic conversation) will be compared with mean of the expert RE group using the T-test; if the null hypothesis (no difference between the groups) can be rejected, the control group will be compared to the student RE group; if the null hypotheses can be rejected here as well the expert RE group will be compared with the student RE group.
As secondary analysis, analysis of covariance (ANCOVA) will be performed with SDNN at day 5 and group as variable and SDNN at baseline as a covariable, if preconditions for ANCOVA are fulfilled. Cohen’s d will be calculated between 2 of the 3 groups and a Cohen’s d > 0.5 will be considered a medium effect size. If parametric tests are not possible, non-parametric tests will be performed and the median with the 25th and 75th percentile reported.
For the other secondary outcomes, the same procedures will be performed and for categorical variables the chi-square test will be used. The paired T-test will be performed in continuous variables to compare characteristics of one group between two time points.
Interim analyses {21b}
No interim analyses are planned.
The coordinating investigator is under obligation to monitor the progress of the clinical trial with regard to safety-relevant developments and, if necessary, initiate the premature termination of a treatment arm or the entire clinical trial.
A treatment arm or the entire clinical trial will be terminated prematurely if:
- the coordinating investigator considers that the termination of the trial is necessary,
- indications arise that the trial patients' safety is no longer guaranteed,
- an insufficient recruitment rate makes a successful conclusion of the clinical trial unrealizable/no longer feasible.
If the clinical trial is prematurely terminated, the ethics committee will be informed by the coordinating investigator.
The trial participant can withdraw consent for trial participation at any time, without having to give reasons.
The responsible investigator may only withdraw a patient from participation in the trial for the following reasons: extreme circumstances arise which make any trial-relevant follow-up impossible.
The documentation should be completed as far as possible under these circumstances, e.g. a final examination and documentation according to the protocol (if possible), a documentation of the premature trial termination on the CRF and in the medical record, giving reasons, should be ensured.
Methods for additional analyses (e.g. subgroup analyses) {20b}
Subgroup analyses will be performed regarding possible confounders such as type of surgery or tumor stage, as these might impact participants’ stress levels.
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Missing data will be imputed by full-information maximum likelihood method. The per-protocol group will be defined as having no missing data in the relevant outcome and having participated in more than 5 of 8 treatments.
Plans to give access to the full protocol, participant level-data and statistical code {31c}
The full protocol is available as additional content to this article. Because of privacy reasons, the full dataset will not be made publicly available.
Oversight and monitoring
Composition of the coordinating center and trial steering committee {5d}
Principal Investigator (PGW) and deputy (GSK):
- Design of the trial
Preparation of protocol and revisions
- Publication of study reports
- Agreement of final protocol
Department of General and Visceral Surgery
- Recruitment of colorectal cancer patients
Team of RE experts
- Organization of patient interventions
- Training of students in RE
Composition of the data monitoring committee, its role and reporting structure {21a}
As the possible harm of the intervention is presumed to be small, no data monitoring committee is planned for this trial.
Adverse event reporting and harms {22}
Complications possibly associated with the intervention will be recorded on a daily basis. Severe complications will be reported immediately to the principal investigator, who then decides about the continuation or discontinuation of the intervention.
Frequency and plans for auditing trial conduct {23}
No auditing is planned
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}
The investigator will report every important protocol modification to the ethics committee of the University Medical Center Freiburg, to the German trials Registry and the respective study staff.
Dissemination plans {31a}
The investigator will prepare a publication of the results of the study and submit it to a peer-reviewed journal. There are no publication restrictions.